CDCA5 and neuroblastoma: Moreover, high expression of some of these identified proteins inhibited by ulixertinib, including CDCA5, ATAD2, CDC25A, CDK2, ANAPC10, RRM2, LRG5, SKP2, CENPM, and UBE2T, are strongly associated with worse overall survival of NB patients (Supplementary Figure S2).